Bora Pharmaceuticals Invests in Tanvex to Provide Global Biomanufacturing Services

Bora Pharmaceuticals is merging its contract development and manufacturing organisation (CDMO) facilities with Tanvex to create a global biologics development and supply service. The transaction will complete in Q1 2025, with Bora holding 30.5% of Tanvex’s shares. The merger will combine Bora’s CDMO capabilities with Tanvex’s skills, scalability and FDA-approved commercial-scale facility. Bora will leverage Tanvex’s new fill/finish facility in Maryland, extending its services to customers worldwide.